Review Article

Therapeutic Activity of Lenalidomide in Mantle Cell Lymphoma and Indolent Non-Hodgkin’s Lymphomas

Table 6

Ongoing lenalidomide-based regime trials.

NamePhaseAgeHistologyDrugsStatus

NCT01415752II>60 ysUntreated MCL Ongoing and recruiting
NCT01316523II>18 ysUntreated indolent NHLRLOngoing and recruiting
NCT00695786II>18 ysUntreated indolent NHLRLOngoing and recruiting
FIL R2-BII>18 ysUntreated indolent NHLRBLOngoing and recruiting

RBV: rituximab, bendamustine, bortezomib; RL: rituximab, lenalidomide; RBL: rituximab, bendamustine, lenalidomide.